The Australian Business Review
Melodiol is making good progress on securing the key European Good Manufacturing Practice (EU GMP) licence that will allow it to export cannabis to the lucrative markets of Australia and Europe.
The company is working with leading North American regulatory and scientific cannabis consulting agency CannDelta to advance the licensing process, which it describes as “well progressed”, for EU GMP – a minimum standard that a medicines manufacturer must meet in its production processes before it can export to several major global markets.
To date, Melodiol Global Health’s (ASX:ME1) wholly-owned subsidiary Mernova Medicinal has completed and submitted its site analysis plan for its manufacturing facility in Nova Scotia, Canada.
The Good Manufacturing Practices site quality risk evaluation had highlighted that minimal additional infrastructure upgrades would be required during the application process – a positive finding that is expected to minimise any major expenditure ahead of scale-up.
Mernova has also completed and passed the Good Agricultural and Collection Practices site quality risk assessment, which is a major milestone in the application process.